...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

"Thanks BDZ,... that symposium sounds super interesting,... is that a sign of confidence,... ? Any chance they will announce TLD here,... if we met Primary Endpoint,...?"

They have been regularly doing symposia at ESC and ERA-EDTA for the past few years. But this is the first one that falls into "the zone" of the expected top-line data timeline. Definitely possible that top-line data is announced during ESC based on current guidance.

BearDownAZ

Share
New Message
Please login to post a reply